 |
 |
 |
|
|
|
|
Alan Paau, Assistant Vice Chancellor, University of California, San Diego. (back
to program)
|
|
Prior to UCSD, Dr. Alan Paau was Executive Director of the Iowa State University Research Foundation, Inc. and Director of Intellectual Property & Technology Transfer at Iowa State University (Ames, IA).
Previously, he was Associate Director of the Biotechnology Center at the Ohio State University (Columbus, OH) with responsibilities in research administration, technology management, and industry liaison. Dr. Paau held faculty appointments while at Iowa State University in the departments of Preventive Medicine, Immunology & Microbiology, and Genetics & Zoology, and at the Ohio State University in the departments of Microbiology, and Plant Pathology.
Before returning to the academic environment, Dr. Paau held various research and management positions in the Cetus Corporation and the W.R. Grace & Co. organization for over 10 years.
Dr. Paau holds a Ph.D. degree in Biological Sciences and a Master of Business Administration degree. He is the inventor to 8 US patents and has contributed thirty peer-reviewed research articles to scientific journals and six invited reviews/chapters to technical books. As a director of intellectual property and a licensing executive, he supervised the execution of over 500 licenses and option agreements and the formation of over 30 startup companies using university innovations.
|
| John Kozarich, President & Chairman, ActivX Biosciences, Inc. (back
to program)
|
|
Dr. Kozarich is President and Chairman of ActivX. He joins ActivX with over 20 years experience in academic and pharmaceutical research. Most recently, he was Vice President at Merck Research Laboratories, where he was responsible for programs including antimicrobial drug discovery, enzymology, 5a-reductase biology, lipid biochemistry, nuclear receptors, ion channels and structural biology. He has been involved in a number of Merck drug programs, including Propecia, Type-1 5a-reductase inhibitor, and MRSA carbapenams. He also has had primary responsibility for a number of Merck collaborations with biotechnology companies, such as Aurora Biosciences, Cubist and KaroBio. In addition, he has played a major role in Merck's acquisition of SIBIA and in the development of its new Boston Research Center. Previously, Dr. Kozarich held faculty positions at the University of Maryland, College Park, and Yale University School of Medicine. He also served as Vice President, Research and Development at Alkermes, a biotechnology company that develops products based on sophisticated drug delivery technologies. Dr. Kozarich is internationally known for his work on enzyme mechanisms and on the chemistry of DNA cleaving antitumor drugs. He was an American Cancer Society Faculty Research Awardee and in 1988 received the Pfizer Award in Enzyme Chemistry of the American Chemical Society for his unique and broad research contributions. He has also served on numerous government and academic committees. Dr. Kozarich has authored over 125 primary scientific publications and holds three patents.
|
| Xiangdong Fu, Professor of Cellular and Molecular Medicine, UCSD. (back
to program)
|
|
Xiang-Dong Fu received his B.S. in Virology (1982) from Wuhan University, mainland china. He was selected to enter a graduate school in the US through the CUSBEA (China-United States Biochemistry and Molecular Biology Examination and Administration) program. After receiving his Ph.D. from Case Western University (1983-1988), and completing his postdoctoral training at Harvard (1988-1992), he joined the faculty of UCSD and is currently an Associate Professor of Cellular and Molecular Medicine. Dr. Fu has been selected as prestigious Searle Scholar (1994-1997) and Leukemia Scholar (1997-2002) for his accomplishments and proposed research in RNA splicing. He is currently a member of the RNA Society and American Association for the Advancement of Science. His research is supported by grants from the NIH.
|
| Joseph D. Panetta, President & CEO, BIOCOM. (back
to program)
|
|
Joseph Panetta is President and CEO and a member of the Board of Directors of BIOCOM, the southern California regional association representing 500 life science companies and the considerable number of service sector firms, universities and research institutes working within the life science arena. As President and CEO, Mr. Panetta is responsible for leading BIOCOM in positioning the region’s life science community to achieve global success in the biotechnology arena. Working with a staff of 15, a 50 member Board of Directors, and a membership consisting of more than 35,000 employees, he directs programs in capital formation, public policy, workforce education, scientific innovation. He also directs a for-profit subsidiary, the BIOCOM Purchasing Group which provides more than $20 million in products and service contracts to members.
Mr. Panetta serves on various regional boards, business coalitions and committees addressing legislation, workforce and economic development issues pertinent to biotechnology. He is currently on the boards of directors of the San Diego Chamber of Commerce, the San Diego Regional Economic Development Corporation, the San Diego Workforce Partnership, and the San Diego World Trade Center. He also serves on the Board of Directors of Gene Therapy Systems, Inc., a San Diego biotechnology company. He is a member of the biotechnology advisory boards at San Diego State University, Cal State University, San Marcos and the Keck Graduate Institute. He is a founder of the San Diego Biotechnology Political Action Committee and Californians United for Research, Economic Development and Saving Lives (CURES). His civic involvement includes serving on the San Diego Public Utilities Advisory Commission which advises the mayor and city council on water related issues.
Mr. Panetta has been actively involved in product development in the government and regulatory affairs arena for more than 25 years, having begun his professional career with the Washington, D.C. headquarters staff of the U.S. Environmental Protection Agency where he became the youngest senior policy analyst within the Reagan Administration. While at the EPA he was also a member of a select group of policy analysts who worked with Administrator Anne Gorsuch to develop the agency’s first strategic plan and goals. In 1984 he left government and joined Pennwalt Corporation, a Fortune 500 pharmaceutical and chemical company, where he led the international regulatory affairs program within the agrichemicals division.
In 1988 he joined Mycogen Corporation, one of San Diego’s first NASDAQ listed biotechnology firms, where he played a principal role in developing safety and efficacy data for and obtaining U.S. and worldwide regulatory approvals of the first genetically engineered microbes and crops. Mr. Panetta served as Vice President of Government and Public Affairs at Mycogen during a period when the company grew to over 600 employees and had sales of $250 million, with offices throughout the world. His global responsibilities included serving as Chairman of Mycogen Mexico, as a board member of Mycogen’s French subsidiary, and as a liaison to Mycogen’s partner firms in Argentina, Chile and Japan. After participating in the divestiture of Mycogen to The Dow Chemical Company in 1998, he served briefly as Global Leader of Government and Regulatory Affairs for the Plant Sciences Division of Dow AgroSciences before taking the helm at BIOCOM.
He has advised the National Academy of the Sciences on biotechnology safety issues, he has been a delegate to the Global Consultation on Safety in Biotechnology under the auspices of the United Nations Environmental Program, and was a representative to the Governor’s Council on Biotechnology under former California Governor Pete Wilson. He testifies regularly before committees of the U.S. Congress and the California legislature on issues regarding biotechnology policy, regulatory affairs and international trade. Mr. Panetta has been recognized for his advocacy work by the American Academy of Pharmaceutical Physicians and the Sidney Kimmel Cancer Center.
In addition to his work as President and CEO of BIOCOM Mr. Panetta’s association involvement has included serving as founding member and chairman of numerous national and international level biotechnology committees including the International Biotechnology Forum under the auspices of the Biotechnology Industry Organization (BIO). He currently serves as Chairman of the BIO Council of State Biotechnology Associations, an organization that coordinates joint efforts of more than 40 regional biotechnology associations nationwide in addressing state and national policy issues and in identifying and adopting best management practices.
Mr. Panetta holds a Bachelor of Science degree in biology from LeMoyne College in Syracuse, NY and a Master of Public Health degree in Industrial and Environmental Health from the University of Pittsburgh. He resides in San Diego with his wife Karin and their two children, Lauren and Christopher. He enjoys participating in outdoor sports including distance running, skiing and biking.
|
| Henry Pan, Chief Medical Officer and Executive Vice President, Neurocrine Biosciences. (back
to program)
|
|
Henry Pan, MD, PhD, FACC, FCP, is currently the Executive Vice President and Chief Medical Officer at Neurocrine Biosciences. He is also an officer of the company. During his three years at Neurocrine, he has built a world class Clinical Development group and has played a pivotal role in progressing the company from one focused in basic research to one that is commercialization ready. Prior to joining Neurocrine, Dr. Pan was an executive at VennWorks LLC, an operating company that creates, builds, and operates high value companies in different technology areas. At VennWorks, he was a Managing Director of the operating company in New York, the CEO of VennWorks RTP in North Carolina, an incubator company that focused in Life Sciences, Chancellor of the Enterprise Factory Institute, and board member of Labnetics Inc., a lab-on-a-chip company in Austin, TX. Prior to joining VennWorks, he was President, CEO, Managing Partner, and co-founder of IDDS and Pharmacologics LLC; President & CEO of MDS Pharmaceutical Services, a fully integrated Contract Research Organization that included MDS Harris, MDS Panlabs, MDS Clinical Trial Laboratories, MDS NeoPharm, MDS Tricon, MDS SCI, Analytical Solutions, Absorption Systems, among others. Dr. Pan also served as Executive Vice President, Drug Development and Medical Affairs at DuPont Merck Pharmaceutical Company, now a Bristol-Myers Squibb Company. While at DuPont Merck he was responsible for building a top-notch drug development team. In addition to his tenure at DuPont Merck, he was Vice President (Head) of Clinical Research and Development at Bristol-Myers Squibb in Princeton, New Jersey. In his years at DuPont Merck and Bristol Myers Squibb he was intimately involved in over 40 NDA’s. He is well recognized in the pharmaceutical industry as one of the very few who has taken a blockbuster drug from pre-IND to launching the product in over 90 countries. He also has over 100 publications to his credit. He has served on the board of more than 15 companies and organizations. Dr. Pan is a Fellow of the American College of Cardiology, the American College of Clinical Pharmacology, the American Heart Association, the Institute of Biological and Clinical Investigation, and the Academy of Medicine of New Jersey.
|
| Alain D. Baron, Senior Vice President of Research, Amylin Pharmaceuticals, Inc. (back
to program)
|
|
Dr. Baron, one of the executive officers of Amylin Pharmaceuticals Inc., has served as the Senior Vice President, Research since June 2002. He previously served as Vice President, Clinical Research since December 1999. Dr. Baron has been clinical Professor of Medicine at the University of California, San Diego, and Clinical VA Staff Physician at the VA Medical Center, San Diego, since 2001. From 1989 to 2000, Dr. Baron worked for the Indiana University School of Medicine, where he served as Professor of Medicine and Director, Division of Endocrinology and Metabolism. Earlier, Dr. Baron held academic and clinical positions in the Division of Endocrinology and Metabolism at the University of California, San Diego, and the Veterans Administration Medical Center in San Diego. He is the recipient of several prestigious awards for his research in diabetes and vascular disease, including the 1996 Outstanding Clinical Investigator Award from the American Federation for Medical Research, several awards from the American Diabetes Association, and is a current National Institutes of Health MERIT award recipient. He earned his M.D. from the Medical College of Georgia, Augusta, and completed postdoctoral studies at the University of California, San Diego.
|
| Evan Snyder, Professor and Director, The Burnham Institute. (back
to program)
|
|
Evan Y. Snyder, M.D., Ph.D., is Professor and Director of the Program in Developmental & Regenerative Cell Biology (The Stem Cell Program) at The Burnham Institute. (He also coordinates The Southern California Stem Cell Consortium). He possesses expertise in stem cell biology (including human), neurobiology, animal models of disease states, and transplantation. A neurobiologist, Dr. Snyder assumed this position last year after many years at Harvard Medical School where he made seminal contributions to understanding the basic biology and therapeutic applications of stem cells in multiple neurological disorders. Although his earliest work involved the use of somatic stem cells derived from rodent and human nervous system (indeed, he was one of the first, if not the first, to identify the neural stem cell), his expertise has now grown to include the mechanisms by which embryonic stem cells (particularly human) differentiate towards neuroectodermal lineages. In fact, this past year he was co-director of an NIH-sponsored course teaching the "hands-on" manipulation and use of human embryonic stem cells (hESCs). He and his lab have a patent pending on the derivation of the "biologics-free" culture conditions for hESCs as well as 2 papers under review describing the minimal molecular requirements as well as the chromatin modifications necessary for the pluripotent state of human ES cells. He and his colleagues have developed and characterized many human NSC populations, as well as the techniques for isolating and generating new stem cell populations [e.g., Nature Biotechnol. 16:1033-1039, 1998; Exp. Neurol. 161:67-84, 2000; Brain Pathol 9:569-598, 1999]. He holds the patents for engraftable human NSCs (hNSCs) [US #5,958,767, #6,680, 198B1, #6,541,255B1]. Dr. Snyder is also board certified in pediatrics, neurology (with special competence in children), and neonatology (newborn intensive care) having completed his clinical post-graduate training at Harvard Medical School and Children's Hospital-Boston. He continues to be clinically active in all these disciplines. His training in basic science include a Ph.D. in neurobiology (Penn) and a postdoctoral fellowship in the Dept. of Genetics, Harvard Medical School where he explored the use of retroviral vectors to study neural plasticity in vitro and in vivo. Having moved to San Diego, he now is also on the faculty of The Department of Pediatrics at UCSD (actively involved clinically) and directs the Basic Science Program in Neonatology.
|
|
Thomas R. Beattie, Biopharma Consultant (back
to program)
|
|
|
Dr. Beattie received a B.S. in chemistry from the University of Pennsylvania, a Ph.D. in physical organic chemistry from the University of Wisconsin, and was a postdoctoral fellow at M.I.T. Since 1998 he has been a consultant in biopharma with many companies: Irori, ChemRx, Maxim Pharmaceuticals, Nereus Pharmaceuticals, Orphagen, AlleCure, Torys LLP, and Somaxon Pharmaceuticals. Prior, he worked full-time at Amylin Pharmaceuticals (4 years) and Merck (27 years) in various aspects of drug discovery. His current professional activities include teaching medchem and combichem at U. Kansas and UCSD Extension, organizing the annual San Diego Medchem/Combichem Symposium, monitoring Gordon Research Conferences, and serving in a variety of functions in ACS local and national activities.
|
|
Henry Li, Director of Oncology, Immusol, Inc. (back
to program)
|
|
Dr. Li currently serves as the Director of Oncology at Immusol, Inc., a San Diego-based biopharmaceutical company. Since joining the company as a scientist in 1996, Dr. Li has been directly responsible for a number of key technology developments in drug target discovery at Immusol, particularly in the area of cancer research. He created the first randomized ribozyme gene library, and was one of the leading scientists to develop Immusol’s phenotype-driven drug target discovery platform, based on the ribozyme library (now including siRNA-libraries) and combinatorial gene silencing (Inverse Genomics®). He has been leading the effort to develop powerful in vivo validation models in cancer therapy as well as treatments for other diseases. Dr. Li has also been directly responsible for several cancer discovery collaborations at Immusol, including multi-year and multi-million dollar Oncology partnerships with Novartis Pharma AG, Medarex and Affymetrix, etc. At present, Dr. Li is directing the oncology research at Immusol, and his team is focusing on discovering novel cancer therapies utilizing Immusol’s innovative biology.
Prior to joining Immusol, Dr. Li received his B.S. in Biology at the University of Science and Technology of China in 1982, M.S. in Biophysics at Fudan University Medical Center in 1985, and Ph.D. in Molecular Biology and Biochemistry at the University of California (Irvine) in 1991. His Ph.D. thesis studied retrovirus induced leukemogenesis. As a postdoctoral fellow and later as a research biologist at the UCLA School of Medicine, Dr. Li conducted researches on human retroviruses including HIV and HTLV as well as on gene therapy.
|
|
Gerhard Frey, Principal Scientist, Diversa Corporation. (back
to program)
|
|
|
Gerhard Frey is a Principal Scientist at Diversa Corporation and a member of American Society for Microbiology and Vereinigung fuer Allgemeine und Angewandte Mikrobiologie. He joined Diversa in 1998 as a Staff Scientist and was promoted to Senior Staff Scientist (2000) and Principal Scientist (2002). Gerhard obtained his Ph.D. in Biology from University of Regensburg, Germany and completed postdoctoral studies at University Kiel, Germany. His research interests focus on the improvement of protein therapeutics with optimal desired characteristics. He is an author of over 12 publications and a (co)inventor of 9 patents.
|
| John Doukas, Senior Director, Cardiovascular Biology, TargeGen. (back
to program)
|
|
Dr. Doukas received a Ph.D. from Boston University, where his thesis addressed the connection between vascular permeability and leukocyte diapedesis. Following a post-doctoral fellowship at Harvard Medical School examining immune functions of the vascular endothelium (under the direction of Dr. Jordan Pober), he moved to faculty positions at the University of Massachusetts Medical School, where his laboratory investigated topics related to endothelial cells and autoimmune inflammation. After positions at Prizm Pharmaceuticals and Selective Genetics, where he contributed to programs that sought to develop growth factor proteins and gene vectors for indications such as wound repair and myocardial ischemia, he joined TargeGen to establish the Cardiovascular Program and where he now guides the development of novel therapeutics for treatment of ischemic diseases. |
| Dawei Zhang, Principal Scientist, Amgen. (back
to program)
|
|
|
Dawei Zhang is a principal scientist at Amgen. After obtaining his B.S. (1990) and M.S. (1992) degrees from Peking University in China, Dawei came to the United States and pursued his Ph.D. in synthetic organic chemistry in Emory University. After receiving his Ph.D. in 1996 and spending one year as a postdoctoral fellow in Emory University, Dr. Zhang moved to southern California in 1997 and worked for a year at Agrouront Pharmaceutical Inc., now part of Pfizer. Then he was recruited to Amgen’s small molecule drug discovery team in 1998 as a research scientist I and was promoted to research scientist II (2001), research scientist III (2003), and principal scientist (2005). His research efforts direct towards the discovery of small molecules for the treatment of inflammatory diseases. He is an author of 7 publications and inventor of 4 patents.
|
| Zeling Cai, Principal Scientist, Johnson & Johnson PRD. (back
to program)
|
|
Zeling Cai is a principal scientist in Johnson & Johnson PRD, an Adjunct Associate Professor at the Sidney Kimmel Cancer Center and a member of American Association of Immunologist and Society of Biotherapy. Zeling obtained her M.D. and M.S in Hematology from Henan Medical University in China. In 1986, she came to the United States working as a clinical fellow in Hematopathology at the University of Minnesota and then pursued her Ph.D. in Immunology at the Mayo Clinic in Rochester Minnesota. After acquiring a Ph.D. in 1992, she received her Post-Doctoral training at The Scripps Research Institute and then joined Johnson & Johnson in 1995. Zeling is a pioneer in the field of cell therapy. In the early1980’, she applied both bone marrow and fetal liver stem cells to treat leukemia patients. Currently, she has developed an artificial antigen presenting cell system for generation of antigen-specific cytotoxic T lymphocytes (CTLs), which has been successfully used in clinical trials for treatment of cancer patients. Her research interests include T cell activation and immunological tolerance. She is an author of over 30 publications and an inventor of 14 patents.
|
|
Wei Chen, Ph.D., Chief Operation Officer, Symbiotix, Inc., San Diego. (back
to program)
|
|
|
Dr. Chen is the Chief Operation Officer of Symbiotix, Inc. Dr. Chen was a co-founder of Symbigene, and served as Chief Executive Officer since its inception. Dr. Chen has held scientific and managerial positions at major biopharmaceutical companies such as Therapeutics Corp., Bristol-Myers Squibb, Immunomedics, BioReliance, and Centorcor/Apollon from 1990 to 1999. He earned his Ph.D. at Nagoya University, Japan, in bioreaction engineering, followed by postdoctoral training in virology, bacteriology, genetics, cell biology, and bioprocessing at the University of British Columbia (1988-1989) and Yale University (1987-1988). He was a faculty member at the Department of Microbiology and Biochemical Engineering of UCLA.
|
|
Hua Jin, Assistant Clinical Professor, Department of Psychiatry, University of California, San Diego. (back
to program)
|
|
Dr. Jin graduated from Shanghai Medical University in 1983 and completed psychiatry residency training at Shanghai Mental Health Institute between 1983 and 1987. Collaborating with neurosciences department at UCSD, he was involved in the first Alzherimer’s dementia study in China that brought him to UCSD in 1987 and 1990. After passing the US medical license examinations, he had psychiatry residency training again in the department of psychiatry at UCSD from 1996 to 2000 and has joined the faculty as an Assistant Clinical Professor in the department since then. His main research interests include geriatric psychiatry, clinical trial, drug related metabolic side effects and HIV/AIDS. Currently, he is the PI for several clinical trials on antipsychotics and antidepressants in the US and China, as well as the co-PI in a large scale HIV/AIDS neuropsychiatry research collaborating between UCSD and China CDC.
|
| Eddie Wang Rodriguez, Principal, Fish & Richardson, P.C. (back
to program)
|
|
Eddie Wang Rodriguez, Principal of Fish & Richardson, was the recipient of ABA’s Business Leadership Award in 2004 and was selected by San Diego Metropolitan as one of "40 of the brightest young professionals, executives, entrepreneurs and civic leaders in San Diego County" under the age of 40 in 2003. Rodriguez's practice focuses on the representation of both public and private companies in a full range of corporate and securities matters, including corporate formation, mergers and acquisitions, venture financing, technology licensing, and general business counseling. He has extensive experience with counseling companies in the life science, software, hardware, telecommunications, e-commerce, and information technology industries in a broad range of transactional matters. Prior to joining Fish & Richardson P.C. in October 2002, Rodriguez was a partner at Brobeck, Phleger & Harrison LLP where he led the mergers and acquisitions group for Brobeck's San Diego office. Rodriguez earned his undergraduate degree from the University of California, Los Angeles and his law degree from Stanford Law School, where he was editor in chief at the Stanford Journal of International Law, and articles editor for the Stanford Law and Policy Review.
He gives freely of his time to many organizations, especially those that focus on the advancement of young companies and entrepreneurs, including the US-CHINA Entrepreneurs Association, UCR CONNECT, UCSD CONNECT, SDSU Business School’s Entrepreneur Society, and the San Diego Chinese Association. |
| Jane Moores, Assistant Director, Technology Transfer and Intellectual Property Services, UCSD
. (back
to program)
|
|
Jane holds B.Sc. and Ph.D. degrees in microbiology from University College, London. She performed post-doctoral research at UCSD in the Chemistry Department, where she was involved in cloning bacterial genes, and in the School of Medicine, where she helped to develop retroviral vectors for gene therapy. After completing her postdoctoral fellowships, Jane spent several years at Stratagene working as a bench scientist, as liaison between engineers and biologists and in various aspects of business development. Jane joined the UCSD TTIPS office at the end of 1999 and has focused on licensing inventions in the life science and biomedical arena with occasional forays into engineering.
|
| Beverly A. Cormier, President, BioScience Business Solutions
. (back
to program)
|
|
Beverly Cormier has significant practical healthcare marketing, sales, and business development expertise spanning the genomics, proteomics, bioinformatics, diagnostics, and device industries. Her experience is relevant to start-up, early, and mid-stage companies.
After earlier healthcare sales experience, in 1990 she was appointed national sales manager for Specialty Laboratories, a full service clinical reference laboratory in southern California. In 1992 she joined UroCor, a urology diagnostics and disease management company based in Oklahoma. Over a 5-year period she held senior positions with this company as western regional manager, director of sales, and director, new business development.
In 1997 Ms. Cormier was recruited to Prometheus, a San Diego-based gastrointestinal disease management company as director of sales, marketing, and business development, and after two years was recruited again to be VP, strategic development for PPGx, a pharmacogenomic solutions start-up.
In July 2000, after PPGx was acquired by DNA Sciences, she started BioScience Business Solutions and has worked with over a dozen clients in a variety of senior management roles. Client relationships have ranged from individual projects to full time contract positions with companies in drug discovery, clinical genomics and clinical diagnostics.
Ms. Cormier graduated cum laude from the University of Cincinnati and did graduate work at Miami University.
|
|
Janet White, Senior Director, Development Business Operations, Pfizer Global R&D, La Jolla. (back
to program)
|
|
Pfizer Inc discovers, develops, manufactures, and markets leading prescription medicines for humans and animals and many of the world's best-known consumer brands. Pfizer boasts the industry's largest pharmaceutical R & D organization, with an annual budget of $7.1 billion Pfizer's search for new treatments spans hundreds of research projects across 18 therapeutic areas - more than any other company.
Janet White is Head of Business Operations for Development at Pfizer’s La Jolla R&D Center. In her current role, Ms. White provides strategic insight and support to Pfizer leadership in a broad range of areas, including strategic planning, resource analysis, business metrics and communications.
Ms. White received her BA degree in Chemistry from Cambridge University in the UK. She then worked for almost ten years as a chemist, in SmithKline Beecham Pharmaceuticals R&D before completing her MBA degree and switching to a career in management consulting within the pharmaceutical industry. Ms. White worked for five years in various consulting firms, including Arthur D. Little and Renaissance in London UK, and then in Phizz Rx, a start-up company that she co-founded, in London, UK and Princeton, NJ, before joining Pfizer in San Diego.
|
|
Hai Mi, Senior Director of Strategic Planning, WuXi PharmaTech, Shanghai, China. (back
to program)
|
|
|
Dr. Mi was a business strategy consultant at Pfizer headquarters in New York where he led a cross-functional group that assisted the implementation of a set of technology initiatives aimed at maximizing commercial values of pipeline candidates and expediting the drug development process. He also was a scientific and business intelligence specialist and a member of two cardiovascular drug development teams at Pfizer Global Research and Development at Ann Arbor, Michigan for three years. In early 2003 he was a senior vice president of MEDiolase, a medical device startup and was responsible for the overall Greater China strategy. Dr. Mi also helped Biopharma Solutions, a New Jersey-based drug delivery technology startup create business plan and seek venture capital funding. He is knowledgeable of the active pharmaceutical ingredient market and was a U.S. representative of East-Asia Pharmaceutical Chemical Company, a large private China API manufacturer. Dr. Mi has an MBA degree from The University of Chicago Graduate School of Business, a Ph.D. in chemistry from New York University, and a B.Sc. in material science from Fudan University, China.
|
|
Weiping Yang, Ph D., Senior VP for Proteomics, CapitalBio Corporation, Beijing, China. (back
to program)
|
|
Dr. Yang obtained his Bachelor's degree in Medicine and Ph. D. degree in Biochemistry from Purdue University (1993). He went to the Scripps Research Institute for postdoctoral training during 1993-1995. Since then, Dr. Yang worked in the Applied Biotech, Stratagene Cloning System, Aviva Bioscience Corporation and assumed various positions. He served as CEO and CTO of Aviva Antibody Corporation. Dr. Yang is an expert on molecular biology as well as molecular immunology. He also has extensive management experiences in both domestic and international Biotech industries.
|
|
| | |
|
|
|
.gif){kind=small}
